---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000003"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:04:47.416206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novocure FY2024 revenue $605M (+19%), Q4 net loss $65.9M; Optune Lua approved and launched; PANOVA-3 trial met endpoint

## Summary
- FY2024 net revenues $605.2M (+19% YoY); Q4 net revenues $161.3M (+21% YoY).
- Q4 net loss $65.9M ($0.61/sh); adjusted EBITDA $2.6M; cash $959.9M.
- Optune Lua received FDA approval Oct 2024 for metastatic NSCLC; 52 prescriptions by year-end.
- Phase 3 PANOVA-3 trial met primary endpoint in unresectable locally advanced pancreatic cancer.
- 2025 outlook: low mid-single digit GBM growth; margins impacted by product launches.

## SEC filing metadata
- accession: 0001645113-25-000003
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000003/0001645113-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000003/nvcr-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000003
- JSON: https://secwatch.observer/filing/0001645113-25-000003.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.